MIAMI, FLORIDA / ACCESS Newswire / October 23, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) (“Telomir” or the “Company”), a pre-clinical biotechnology company developing therapies that target ...
New findings highlight Telomir-1’s impact on CASP8 and GSTP1, two critical genes that regulate cell death and glutathione-based detoxification pathways often disrupted in cancer. MIAMI, FLORIDA / ...
Findings complement previously announced results in triple-negative breast cancer (TNBC) and prostate cancer models, highlighting Telomir-1’s consistent impact on cancer cell survival pathways. MIAMI, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback